The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity.
about
Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration-Approved Drugs.OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity.Cutting down the time to identify challenging tumor therapeutic targets and drug combinations using synthetic lethal approaches.New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling.Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen.
P2860
The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
The National Cancer Institute ...... Enhanced Therapeutic Activity.
@en
The National Cancer Institute ...... Enhanced Therapeutic Activity.
@nl
type
label
The National Cancer Institute ...... Enhanced Therapeutic Activity.
@en
The National Cancer Institute ...... Enhanced Therapeutic Activity.
@nl
prefLabel
The National Cancer Institute ...... Enhanced Therapeutic Activity.
@en
The National Cancer Institute ...... Enhanced Therapeutic Activity.
@nl
P2093
P2860
P1433
P1476
The National Cancer Institute ...... Enhanced Therapeutic Activity.
@en
P2093
Apurva Srivastava
Deborah Wilsker
Eric Polley
James A Crowell
James H Doroshow
Jerry M Collins
Larry Rubinstein
Lawrence W Anderson
Melinda Hollingshead
Richard Camalier
P2860
P304
P356
10.1158/0008-5472.CAN-17-0489
P407
P577
2017-04-26T00:00:00Z